FY2025 EPS Estimates for Sanara MedTech Raised by Analyst

Key Points

• Analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Sanara MedTech to ($0.88) per share, significantly up from a previous estimate of ($1.78).
• HC Wainwright increased its price target on Sanara MedTech from $51.00 to $53.00, maintaining a "buy" rating for the stock.
• Institutional investors, including Marshall Wace LLP and Renaissance Technologies LLC, have substantially increased their stakes in Sanara MedTech, indicating growing confidence in the company's prospects.

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for Sanara MedTech in a research report issued to clients and investors on Thursday, August 14th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.88) for the year, up from their prior forecast of ($1.78). The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share. Cantor Fitzgerald also issued estimates for Sanara MedTech's FY2026 earnings at ($0.16) EPS.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.10. Sanara MedTech had a negative net margin of 10.22% and a negative return on equity of 26.43%. The business had revenue of $25.83 million for the quarter, compared to analysts' expectations of $25.15 million.

Separately, HC Wainwright boosted their price objective on Sanara MedTech from $53.00 to $54.00 and gave the company a "buy" rating in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $50.00.

Sanara MedTech Trading Up 11.2%

SMTI stock traded up $3.43 during midday trading on Monday, hitting $33.95. The company had a trading volume of 93,685 shares, compared to its average volume of 44,310. The company has a current ratio of 2.26, a quick ratio of 2.03 and a debt-to-equity ratio of 1.25. Sanara MedTech has a 52 week low of $23.53 and a 52 week high of $39.08. The stock's 50 day moving average price is $27.92 and its 200 day moving average price is $30.34. The stock has a market cap of $302.16 million, a price-to-earnings ratio of -29.27 and a beta of 1.26.

Hedge Funds Weigh In On Sanara MedTech

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its stake in shares of Sanara MedTech by 8,423.8% during the first quarter. GAMMA Investing LLC now owns 1,790 shares of the company's stock valued at $58,000 after buying an additional 1,769 shares during the period. Wells Fargo & Company MN increased its stake in shares of Sanara MedTech by 53.9% during the fourth quarter. Wells Fargo & Company MN now owns 1,893 shares of the company's stock valued at $63,000 after buying an additional 663 shares during the period. MetLife Investment Management LLC purchased a new position in shares of Sanara MedTech during the first quarter valued at approximately $82,000. Lazard Asset Management LLC increased its stake in shares of Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock valued at $89,000 after buying an additional 3,155 shares during the period. Finally, BNP Paribas Financial Markets purchased a new position in shares of Sanara MedTech during the fourth quarter valued at approximately $106,000. 8.10% of the stock is owned by hedge funds and other institutional investors.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.